Praxis Precision Medicines publishes corporate presentation on CNS pipeline, near-term regulatory catalysts

Praxis Precision Medicines

Praxis Precision Medicines

PRAX

0.00
  • Praxis Precision Medicines outlined a late-stage CNS portfolio with two pending FDA decisions, targeting relutrigine action date of Sep. 27, 2026 under Priority Review, followed by ulixacaltamide action date of Jan. 29, 2027.
  • Ulixacaltamide Phase 3 ESSENTIAL3 program in essential tremor showed a Day 56 mADL11 change from baseline of -4.3 versus -1.7 for placebo, with p<0.0001; a randomized-withdrawal study showed 55% maintained response versus 33% on placebo.
  • Relutrigine NDA was accepted for SCN2A- and SCN8A-developmental and epileptic encephalopathies; company also guided to topline EMERALD data in Q4 2026 for broader phenotypic DEEs.
  • Pipeline update also flagged topline POWER1 data in Q2 2026 with POWER3 initiation planned in 1H 2026, with EMBRAVE3 completion anticipated in 2027.
  • Praxis projected portfolio peak sales potential above USD 20 billion, citing ulixacaltamide above USD 10 billion, relutrigine above USD 5 billion, vormatrigine above USD 4 billion; cash runway guided into 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.